Market Place
Sourcing Support
FDA Review Update on VTAMA® (Tapinarof) for Atopic Dermatitis
05 Nov 2024 //
BUSINESSWIRE
Organon Acquires Dermavant, Including VTAMA® (tapinarof) Cream
28 Oct 2024 //
#N/A
Organon Acquires Dermavant, Including VTAMA® Cream
28 Oct 2024 //
BUSINESSWIRE
Dermavant Presents VTAMA® Data for Atopic Dermatitis at Conference
25 Oct 2024 //
BUSINESSWIRE
Dermavant announces approval of Tapinarof for psoriasis and atopic dermatitis
25 Jun 2024 //
BUSINESSWIRE
Dermavant VTAMA Atopic Dermatitis Data Published In JAAD
21 May 2024 //
BUSINESSWIRE
Dermavant`s VTAMA® sNDA Accepted for Atopic Dermatitis in ?2 Years
29 Apr 2024 //
BUSINESSWIRE
Dermavant Presents New Data on Treatment of Patients with Skin of Color
08 Mar 2024 //
BUSINESSWIRE
Dermavant to Present Data for Patients with Skin of Color from Phase 3 of VTAMA
01 Mar 2024 //
BUSINESSWIRE
Dermavant Submits sNDA for VTAMA Cream for the Treatment of Atopic Dermatitis
14 Feb 2024 //
BUSINESSWIRE
Dermavant Announces Positive Data from Phase 3 in Atopic Dermatitis with VTAMA®
11 Jan 2024 //
BUSINESSWIRE
Dermavant Announces Positive Results from Phase 4 Open-Label Trial of VTAMA
06 Dec 2023 //
BUSINESSWIRE
Dermavant Presents Positive Results from Phase 4 Open-Label Trial of VTAMA
20 Oct 2023 //
BUSINESSWIRE
Dermavant to Present New Positive Data from Phase 4 of VTAMA
16 Oct 2023 //
BUSINESSWIRE
Dermavant Announces New Positive Pruritus Data for VTAMA
12 Oct 2023 //
BUSINESSWIRE
Dermavant to Present Data from ADORING 1 and 2 Pivotal Phase 3 Trials of VTAMA
06 Oct 2023 //
BUSINESSWIRE
Dermavant bolsters Vtama`s case for approval in eczema
16 May 2023 //
FIERCE PHARMA
Dermavant Reports Results from ADORING 2 Atopic Dermatitis PIII of VTAMA
15 Mar 2023 //
BUSINESSWIRE
Dermavant`s Vtama cream hits goal in first eczema phase 3 study
15 Mar 2023 //
FIERCE PHARMA
Dermavant to Present Data from Multiple Studies of VTAMA
10 Mar 2023 //
BUSINESSWIRE
Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA cream
13 Feb 2023 //
BUSINESSWIRE
Dermavant to Present Data from Multiple Studies of VTAMA cream
12 Jan 2023 //
BUSINESSWIRE
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Dermavant to Present Data from Multiple Clinical Trials of VTAMA at
13 Oct 2022 //
BUSINESSWIRE
Dermavant to Present New Data from Phase 3 Trial Program of VTAMA cream
24 Aug 2022 //
BUSINESSWIRE
Roivant Sciences Reports Financial Results for the First Quarter
15 Aug 2022 //
GLOBENEWSWIRE
Innovaderm Shines as Key Partner in Clinical Development and Study Managemen
21 Jul 2022 //
BUSINESSWIRE
VTAMA (tapinarof) Cream, 1% PSOARING 3 Final Data Published in JAAD
28 Jun 2022 //
BUSINESSWIRE
FDA Approves Dermavant`s VTAMA (tapinarof) cream for Psoriasis in the U.S.
24 May 2022 //
GLOBENEWSWIRE
Dermavant Shows Durability and Tolerability Data from Phase 3 PSOARING 3 Trial
25 Mar 2022 //
BUSINESSWIRE
Dermavant Presents NPS Data from PSOARING 3 Long Term Extension Trial
15 Jan 2022 //
BUSINESSWIRE
Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 WCDC
07 Jan 2022 //
BUSINESSWIRE
Even as topical, shaking JAK concerns may be tough for Opzelura
12 Nov 2021 //
FIERCEPHARMA
Dermavant Announces Tapinar of Data Presentation at the Innovations
11 Mar 2021 //
BUSINESSWIRE
Dermavant Announces Presentation of Tapinarof Pivotal Ph3 PSOARING Data
22 Oct 2020 //
BUSINESSWIRE
Dermavant Announces Publication in JAAD of Tapinarof Cream phase 2
17 Jun 2020 //
PRESS RELEASE
Dermavant Announces Publication in JAAD Phase 2b Clinical Trial of Tapinarof
16 Jun 2020 //
BUSINESSWIRE
Dermavant Completes Patient Enrollment for Long-Term Safety Study of Tapinarof
09 Jun 2020 //
BUSINESSWIRE
Dermavant Announces Pub in JAAD of 2ndary Efficacy Ph 2b Trial of Tapinarof
26 May 2020 //
DERMAVANT
Dermavant Announces Publication in JAAD Ph 2b Clinical Trial of Tapinarof
26 May 2020 //
BUSINESSWIRE
Dermavant bags $100M for latest Ph3 gamble while Urovant dives into gene therapy
29 Aug 2018 //
ENDPTS
Roivant appoints NEA partner Torti to oversee its ‘vant’ subsidiaries
28 Aug 2018 //
FIERCE BIOTECH
Dermavant inks $330M deal for GSK`s phase 3-ready psoriasis drug
13 Jul 2018 //
FIERCE BIOTECH
